Destabilization of ROR1 enhances activity of Ibrutinib against chronic lymphocytic leukemia in vivo
نویسندگان
چکیده
منابع مشابه
Beyond Ibrutinib Resistance in Chronic Lymphocytic Leukemia
Despite ibrutinib activity in multiple B-cell malignancies, cases of primary and secondary resistance have emerged. The overall reported frequency of resistance is low. Resistance has been found to be caused by a mutation in the BTK binding site of ibrutinib or gain-of-function mutations in PLCG2, which lead to autonomous BCR activity. Improved understanding of mechanisms of primary and seconda...
متن کاملIbrutinib resistance in chronic lymphocytic leukemia.
n engl j med 370;24 nejm.org june 12, 2014 2352 portant questions both about the nature of the evidence and about its sufficiency, a topic that has been the subject of inquiry and discussion in the patient-safety community for well over a decade.1 As noted in the editorial, replications have confirmed substantial effects regarding the use of a surgical checklist, but rigorous randomized trials ...
متن کاملEvolution of ibrutinib resistance in chronic lymphocytic leukemia (CLL).
The Bruton tyrosine kinase inhibitor (BTKi) ibrutinib is a new targeted therapy for patients with chronic lymphocytic leukemia (CLL). Ibrutinib is given orally on a continuous schedule and induces durable remissions in the majority of CLL patients. However, a small proportion of patients initially responds to the BTKi and then develops resistance. Estimating the frequency, timing, and individua...
متن کاملOutcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib.
Ibrutinib is a Bruton tyrosine kinase inhibitor approved for the treatment of patients with relapsed refractory chronic lymphocytic leukemia (RR-CLL). We describe the characteristics, causes of discontinuation, and outcomes in patients who discontinued treatment with ibrutinib. One hundred twenty-seven patients were enrolled in various clinical trials of ibrutinib, with or without rituximab, at...
متن کاملSpontaneous Immunity Against the Receptor Tyrosine Kinase ROR1 in Patients with Chronic Lymphocytic Leukemia
BACKGROUND ROR1 is a receptor tyrosine kinase expressed in chronic lymphocytic leukemia (CLL) and several other malignancies but absent in most adult normal tissues. ROR1 is considered an onco-fetal antigen. In the present study we analysed spontaneous humoral and cellular immunity against ROR1 in CLL patients. MATERIALS AND METHODS Antibodies against ROR1 were analysed in 23 patients and 20 ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Pharmacological Research
سال: 2020
ISSN: 1043-6618
DOI: 10.1016/j.phrs.2019.104512